Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 5:45 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 308 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: lipitor Clear all
Completed Phase 3 Interventional Results available

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

NCT01663402
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Alirocumab, Placebo, LMT
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years and older
Enrollment
18,924 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
273
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 218 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Nov 14, 2026, 5:45 PM EST
Completed Early Phase 1 Interventional

A Pre-Op Window Study Evaluating Anti-Proliferative Effects of Atorvastatin on the Endometrium

NCT02767362
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Atorvastatin
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Nov 14, 2026, 5:45 PM EST
Completed Phase 3 Interventional Results available

Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood

NCT00639158
View directory record Official record
Conditions
Dyslipidemias, Coronary Heart Disease, Combined (Atherogenic) Dyslipidemia, Mixed Dyslipidemia
Interventions
ABT-335, placebo, atorvastatin, ezetimibe
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
543 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
118
States / cities
Birmingham, Alabama • Columbiana, Alabama • Hueytown, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2011 · Synced Nov 14, 2026, 5:45 PM EST
Terminated Phase 3 Interventional Results available

Ezetimibe in Patients Hypo-responsive to Statins

NCT00965055
View directory record Official record
Conditions
High Cholesterol, Coronary Artery Disease
Interventions
Ezetimibe, Atorvastatin
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Nov 14, 2026, 5:45 PM EST
Completed Phase 3 Interventional Results available

Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)

NCT01730040
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Atorvastatin, Ezetimibe, Rosuvastatin, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
56
States / cities
Mobile, Alabama • Chandler, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2015 · Synced Nov 14, 2026, 5:45 PM EST
Terminated Phase 4 Interventional Results available

Risk Factor Control Before Orthopedic Surgery

NCT01837069
View directory record Official record
Conditions
Osteoarthritis, Cardiovascular Disease
Interventions
Metoprolol, Lisinopril, Atorvastatin, Lifestyle counseling
Drug · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Nov 14, 2026, 5:45 PM EST
Completed Phase 2 Interventional Results available

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin

NCT01218204
View directory record Official record
Conditions
Dyslipidaemias, Dyslipidemias
Interventions
10mg atorvastatin, 80mg atorvastatin, GSK1292263 Placebo, 100mg GSK1292263, 300mg GSK1292263, 800mg GSK1292263, 10mg ezetimibe, Washout
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
21
States / cities
Anniston, Alabama • Chula Vista, California • Stockton, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Nov 14, 2026, 5:45 PM EST
Recruiting Early Phase 1 Interventional

Post-Operative Biomarker-Guided Precision Medicine For Cardiovascular Risk Reduction

NCT06961630
View directory record Official record
Conditions
Myocardial Injury After Noncardiac Surgery
Interventions
Rivaroxaban, Atorvastatin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
45 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Nov 14, 2026, 5:45 PM EST
Terminated Not applicable Interventional Results available

Effect of a Fibrate and a Statin on Endothelial Dysfunction

NCT00491400
View directory record Official record
Conditions
Diabetes Mellitus, Metabolic Syndrome
Interventions
Fenofibrate, Atorvastatin
Drug
Lead sponsor
Boston University
Other
Eligibility
30 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Nov 14, 2026, 5:45 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Bioequivalence Study Comparing A New 80 Mg Atorvastatin Tablet To A 80 Mg Atorvastatin Commercial Tablet

NCT00917644
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Atorvastatin, Atorvastatin
Drug · Genetic
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Nov 14, 2026, 5:45 PM EST
Recruiting Phase 1 Interventional

Vascular Endothelial Dysfunction in Sleep Apnea

NCT05289063
View directory record Official record
Conditions
Obstructive Sleep Apnea of Adult
Interventions
Atorvastatin 10mg, Placebo, Continuous Positive Airway Pressure Therapy
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Nov 14, 2026, 5:45 PM EST
Completed Phase 4 Interventional

Do HMG CoA Reductase Inhibitors Affect Abeta Levels?

NCT00303277
View directory record Official record
Conditions
Alzheimer's Disease, Aging
Interventions
simvastatin, pravastatin
Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 90 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 13, 2010 · Synced Nov 14, 2026, 5:45 PM EST
Active, not recruiting Phase 1 Interventional

A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies

NCT03560882
View directory record Official record
Conditions
Malignant Disease, Solid Tumor, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Cancer, Relapsed Hematologic Malignancy
Interventions
Atorvastatin
Drug
Lead sponsor
Joaquina Baranda
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Fairway, Kansas
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Nov 14, 2026, 5:45 PM EST
Completed No phase listed Observational

Diabetic Treatment Adherence

NCT01318564
View directory record Official record
Conditions
Endocrine System Diseases
Interventions
Metformin, Questionnaires
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2016 · Synced Nov 14, 2026, 5:45 PM EST
Completed Phase 2 Interventional Results available

Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation

NCT01525407
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Atorvastatin Calcium, Peripheral Blood Stem Cell Transplantation
Procedure · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Stanford, California • Denver, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Nov 14, 2026, 5:45 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of Multiple Doses of Isavuconazole and Single Dose of Atorvastatin

NCT01635946
View directory record Official record
Conditions
Pharmacokinetics of Isavuconazole, Pharmacokinetics of Atorvastatin, Healthy Volunteers
Interventions
Isavuconazole, atorvastatin
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Nov 14, 2026, 5:45 PM EST
Completed Phase 3 Interventional Results available

An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME)

NCT00465088
View directory record Official record
Conditions
Hyperlipidemia, Mixed Dyslipidemia
Interventions
Niacin ER/Simvastatin Tablets, atorvastatin
Drug
Lead sponsor
Abbott
Industry
Eligibility
21 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
46
States / cities
Anaheim, California • Huntington Park, California • Long Beach, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2011 · Synced Nov 14, 2026, 5:45 PM EST
Completed Phase 2 Interventional Results available

Atorvastatin to Treat Pulmonary Sarcoidosis

NCT00279708
View directory record Official record
Conditions
Sarcoidosis, Pulmonary
Interventions
Atorvastatin, Placebo Oral Tablet
Drug · Other
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Nov 14, 2026, 5:45 PM EST
Active, not recruiting Not applicable Interventional

A Study for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients

NCT03127631
View directory record Official record
Conditions
Prostate Cancer, Cardiovascular Disease
Interventions
Nutrition, Exercise, Smoking cessation, Statin (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin), ACE inhibitor
Behavioral · Drug
Lead sponsor
McMaster University
Other
Eligibility
45 Years and older · Male only
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
4
States / cities
Augusta, Georgia • Kansas City, Kansas • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Nov 14, 2026, 5:45 PM EST
Completed Phase 2 Interventional Results available

Atorvastatin as GVHD Prophylaxis for Allogeneic Hematopoietic Cell Transplantation

NCT01665677
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Atorvastatin calcium
Drug
Lead sponsor
Mehdi Hamadani
Other
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
2
States / cities
Morgantown, West Virginia • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Nov 14, 2026, 5:45 PM EST
Completed Phase 2 Interventional Results available

A Study of LY2484595 in Patients With High LDL-C or Low HDL-C

NCT01105975
View directory record Official record
Conditions
Dyslipidemia
Interventions
LY2484595, Atorvastatin, Simvastatin, Rosuvastatin, Placebo for LY2484595, Placebo for Statins
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
38
States / cities
Fayetteville, Arkansas • San Diego, California • Spring Valley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Nov 14, 2026, 5:45 PM EST
Recruiting Phase 1 Interventional

Novel Approaches for Improving Vascular Function in Veterans With HFpEF

NCT06312748
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction, Inflammation
Interventions
L-Citrulline, Placebo for L-Citrulline, BH4, Placebo for BH4, Atorvastatin, Placebo for Atorvastatin
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Nov 14, 2026, 5:45 PM EST
Not yet recruiting Phase 2Phase 3 Interventional

A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID

NCT06974084
View directory record Official record
Conditions
Long COVID
Interventions
Maraviroc (MVC), Atorvastatin, 10mg, 20mg, 40mg, Placebo, Maraviroc, Placebo, Atorvastatin
Drug
Lead sponsor
HealthBio, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Nov 14, 2026, 5:45 PM EST
Terminated Phase 3 Interventional

VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome

NCT01130246
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
A-002, varespladib methyl, Placebo
Drug
Lead sponsor
Anthera Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
5,189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
83
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 67 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Nov 14, 2026, 5:45 PM EST